YKL-40 acts as an angiogenic factor to promote tumor angiogenesis

被引:110
作者
Shao, Rong [1 ,2 ]
机构
[1] Univ Massachusetts, Morrill Sci Ctr, Mol & Cellular Biol Program, Amherst, MA 01003 USA
[2] Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA
关键词
YKL-40; angiogenesis; VEGF; tumor cells; vascular endothelial cells; tumor-associated macrophages; tumor microenvironment; neutralizing anti-YKL-40 antibody; SMOOTH-MUSCLE-CELLS; BREAST-CANCER; SERUM YKL-40; MACROPHAGE INFILTRATION; GENE-EXPRESSION; PROTEIN YKL-40; PLASMA YKL-40; RHEUMATOID-ARTHRITIS; INSULIN-RESISTANCE; MALIGNANT GLIOMAS;
D O I
10.3389/fphys.2013.00122
中图分类号
Q4 [生理学];
学科分类号
071003 [生理学];
摘要
A secreted glycoprotein YKL-40 also named chitinase-3-like-1 is normally expressed by multiple cell types such as macrophages, chondrocytes, and vascular smooth muscle cells. However, a prominently high level of YKL-40 was found in a wide spectrum of human diseases including cancers and chronic inflammatory diseases where it was strongly expressed by cancerous cells and infiltrating macrophages. Here, we summarized recent important findings of YKL-40 derived from cancerous cells and smooth muscle cells during tumor angiogenesis and development. YKL-40 is a potent angiogenic factor capable of stimulating tumor vascularization mediated by endothelial cells and maintaining vascular integrity supported by smooth muscle cells. In addition, YKL-40 induces FAK-MAPK signaling and up-regulates VEGF receptor 2 in endothelial cells; but a neutralizing antibody (mAY) against YKL-40 inhibits its angiogenic activity. While YKL-40 is essential for angiogenesis, little is known about its functional role in tumor-associated macrophage (TAM)-mediated tumor development. Therefore, significant efforts are urgently needed to identify pathophysiological function of YKL-40 in the dynamic interaction between tumor cells and TAMs in the tumor microenvironment, which may offer substantial mechanistic insights into tumor angiogenesis and metastasis, and also point to a therapeutic target for treatment of cancers and other diseases.
引用
收藏
页数:9
相关论文
共 94 条
[1]
RECEPTOR-BINDING AND HEPARIN-BINDING DOMAINS OF BASIC FIBROBLAST GROWTH-FACTOR [J].
BAIRD, A ;
SCHUBERT, D ;
LING, N ;
GUILLEMIN, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (07) :2324-2328
[2]
The syndecan-1 ectodomain regulates αvβ3 integrin activity in human mammary carcinoma cells [J].
Beauvais, DLM ;
Burbach, BJ ;
Rapraeger, AC .
JOURNAL OF CELL BIOLOGY, 2004, 167 (01) :171-181
[3]
Modes of resistance to anti-angiogenic therapy [J].
Bergers, Gabriele ;
Hanahan, Douglas .
NATURE REVIEWS CANCER, 2008, 8 (08) :592-603
[4]
High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia [J].
Bergmann, OJ ;
Johansen, JS ;
Klausen, TW ;
Mylin, AK ;
Kristensen, JS ;
Kjeldsen, E ;
Johnsen, HE .
CLINICAL CANCER RESEARCH, 2005, 11 (24) :8644-8652
[5]
Functions of cell surface heparan sulfate proteoglycans [J].
Bernfield, M ;
Götte, M ;
Park, PW ;
Reizes, O ;
Fitzgerald, ML ;
Lincecum, J ;
Zako, M .
ANNUAL REVIEW OF BIOCHEMISTRY, 1999, 68 :729-777
[6]
The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies [J].
Bingle, L ;
Brown, NJ ;
Lewis, CE .
JOURNAL OF PATHOLOGY, 2002, 196 (03) :254-265
[7]
Contribution of CXCL12 secretion to invasion of breast cancer cells [J].
Boimel, Pamela J. ;
Smirnova, Tatiana ;
Zhou, Zhen Ni ;
Wyckoff, Jeffrey ;
Park, Haein ;
Coniglio, Salvatore J. ;
Qian, Bin-Zhi ;
Stanley, E. Richard ;
Cox, Dianne ;
Pollard, Jeffrey W. ;
Muller, William J. ;
Condeelis, John ;
Segall, Jeffrey E. .
BREAST CANCER RESEARCH, 2012, 14 (01)
[8]
In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases [J].
Bonneh-Barkay, Dafna ;
Wang, Guoji ;
Starkey, Adam ;
Hamilton, Ronald L. ;
Wiley, Clayton A. .
JOURNAL OF NEUROINFLAMMATION, 2010, 7
[9]
CLONING OF A CDNA-ENCODING CHITOTRIOSIDASE, A HUMAN CHITINASE PRODUCED BY MACROPHAGES [J].
BOOT, RG ;
RENKEMA, GH ;
STRIJLAND, A ;
VANZONNEVELD, AJ ;
AERTS, JMFG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (44) :26252-26256
[10]
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane [J].
Burstein, Harold J. ;
Elias, Anthony D. ;
Rugo, Hope S. ;
Cobleigh, Melody A. ;
Wolff, Antonio C. ;
Eisenberg, Peter D. ;
Lehman, Mary ;
Adams, Bonne J. ;
Bello, Carlo L. ;
DePrimo, Samuel E. ;
Baum, Charles M. ;
Miller, Kathy D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) :1810-1816